Study M673
Study name | Xue SS 2020 |
Title | The impact of repetitive transcranial magnetic stimulation and fluoxetine on the brain lipidome in a rat model of chronic unpredictable stress |
Overall design | In this study, the antidepressive effects of repetitive transcranial magnetic stimulation (rTMS) and fluoxetine treatments were assessed using a chronic unpredictable stress (CUS) model in rats. Changes in lipid composition in the hippocampus and prefrontal cortex (PFC) were evaluated using a mass spectrometry-based lipidomic approach. Sprague-Dawley rats were divided into the following 4 groups (n = 8 in each group): (1) control group (no stress, sham rTMS and vehicle injections), (2) CUS group (stress, sham rTMS and vehicle injections), (3) CUS + rTMS group (stress, real rTMS treatment and vehicle injections), and (4) CUS + fluoxetine group (stress, sham rTMS treatment and fluoxetine injections, 10 mg/kg). The CUS stress procedure lasted for 4 weeks, and rTMS and fluoxetine were administered for a week after stress. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Rat; Sprague-Dawley rat; |
Categories of depression | Animal model; Chronic mild stress model; Chronic mild stress model; |
Criteria for depression | Sucrose preference test, forced swimming test |
Sample size | 32 |
Tissue | Central; Brain; Prefrontal cortex; Central; Brain; Hippocampus; |
Platform | MS-based; LC-MS: ultra-HPLC with Q ExactiveTM plus mass spectrometer; |
PMID | |
DOI | |
Citation | Xue SS, Zhou CH, Xue F, et al. The impact of repetitive transcranial magnetic stimulation and fluoxetine on the brain lipidome in a rat model of chronic unpredictable stress. Prog Neuropsychopharmacol Biol Psychiatry. 2020;102:109946. |
Metabolite | LysoPC(0:0/18:0); Phosphatidylethanolamine; Phosphatidylinositol; Glucosylceramides; Ceramides; Ceramide phosphates; Diglyceride; Triglyceride; Monoglyceride; PS(39:0)-H; PG(16:0/18:1)-H; PG(18:0/20:4)-H; PE(34:1e)+H; PE(18:1p/18:1)+H; PE(18:0p/18:1)+H; PE(18:0/20:4)+H; PE(16:0/20:4)-H; PE(18:0/18:2)-H; PE(20:1/18:1)-H; PE(22:5/18:2)-H; PC(36:3)+H; PC(38:5)+H; PC(38:2)+H; PC(40:2p)+H; PC(40:2)+H; PC(14:0/20:4)+HCOO; PC(18:0p/18:1)+HCOO; MGDG(16:0/16:0)+Na; DG(18:0/20:4)+NH4; CerG1(d18:2/24:0+O)+H; CerG1(d18:0+pO/24:1)+H; PS(18:1/18:1)+H; LysoPE(18:0)-H; Phosphatidic acid; Acyl carnitines; Sphingomyelin; SM(d22:1/16:0)+HCOO; PS(18:0/20:4)+H; PS(46:2)-H; PE(34:0p)-H; PC(36:4e)+H; PC(38:7)+H; Cer(d18:1/24:1)+H; SM(d16:1/18:0)+HCOO; PE(16:0p/20:4)+H; PE(16:0p/22:4)+H; PE(18:1p/20:2)+H; PE(38:1e)-H; PC(40:7)+H; PC(18:0/22:6)+H; PC(34:1)+H; PC(36:4p)+H; PA(18:0/18:1)-H; PA(18:0/22:6)-H; PE(18:0e/18:1)+H; PC(16:0/22:6)+HCOO; PA(46:7)-H; LysoPC(18:0)+HCOO; DG(18:0/22:4)+NH4; SM(d40:1)+H; PS(18:0/22:3)-H; PE(18:0p/20:1)+H; PE(18:1p/22:4)+H; PC(36:2e)+H; PA(48:6)-H; MGDG(16:0/18:0)+HCOO; CerG1(d18:1/20:0)+H; PS(41:1)-H; PE(16:0e/22:6)-H; PE(18:0p/22:5)-H; PC(42:1)+H; PC(40:4)+H; PE(18:1p/20:1)+H; PE(16:0p/22:5)-H; PE(18:1/20:4)-H; PE(18:0/20:4)-H; PE(18:1p/22:6)-H; PE(18:0p/22:4)-H; PC(33:0)+H; PC(36:1e)+H; PC(36:0)+H; PC(38:4)+H; PC(18:0/20:4)+H; |
